Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 14 de 14
Filter
1.
Public Health ; 225: 285-290, 2023 Dec.
Article in English | MEDLINE | ID: mdl-37956640

ABSTRACT

OBJECTIVES: Cardiovascular disease (CVD) and associated risk factors within the prison population often present at a younger age in this cohort. Given CVD is largely preventable, it warrants investigation to fully quantify this risk. This study explored the relative predicted 10-year CVD risk and examined the calculated heart age in a representative sample of male individuals aged 25-84 years within the prison environment. STUDY DESIGN: This was a cross-sectional study. METHODS: Data were collected on 299 men who underwent a cardiometabolic risk assessment in HMP Parc, Bridgend. The QRISK2 algorithm was used to calculate 10-year CVD risk, relative risk (to general population) and the predicted heart age of an individual. Between-group differences (prison population vs general community) in cardiovascular risk predictions (10-year CVD risk and heart age) were assessed. RESULTS: We observed that at all age groups, the relative risk of predicted 10-year CVD scores in the prison population was double that of the community risk (2.1 ± 0.6), and this was most apparent in the oldest age group (≥50 years: 17.0% compared to 8.8%; P < 0.001). Overall, the heart age of the sample was 7.5 (6.7-8.2) years higher than their own chronological age, and this difference increased to above 9 years in those aged ≥40 years. CONCLUSIONS: This study provides quantifiable evidence to the elevated CVD risk in prison. Heart age predictions were almost a decade higher in those aged ≥40 years. Lowering the screening age for CVD by around 5 years in the prison population should be considered.


Subject(s)
Cardiovascular Diseases , Humans , Male , Cardiovascular Diseases/epidemiology , Cardiovascular Diseases/prevention & control , Cross-Sectional Studies , Prisons , Risk Factors , Risk Assessment
3.
Hum Vaccin Immunother ; 13(10): 2352-2356, 2017 10 03.
Article in English | MEDLINE | ID: mdl-28708951

ABSTRACT

Incidence of hepatitis A in Wales is low (average of 0.48/100,000 inhabitants from 2004-2015). We describe a community outbreak of hepatitis A involving 3 schools (primary and secondary) in South Wales between March and June 2016 and reflect on the adequacy of the control measures used. Anyone in South Wales epidemiologically linked to a serological and/or RNA positive confirmed case of hepatitis A during the 15-50 d before onset of symptoms (diarrhea, vomiting, fever, nausea, AND jaundice, or jaundice-associated symptom) was defined as a case. Case identification was based on laboratory or GP suspicion notification, changing to active surveillance toward the end. As per national guidance, household contacts were identified and offered immunisation while in schools vaccination followed evidence of transmission. We went beyond guidance by vaccinating street play mates and in secondary schools. Mass vaccination uptake was calculated. There were 17 cases, mostly in children under 16 y of age. All cases had an epidemiological link to either a school or a household case (except primary) and no travel history. Street playing was the only epidemiological link between 2 cases in different schools. A total of 139 household contacts were identified. All schools, including secondary one, had a transmission event preceding mass vaccination (overall uptake 85%, reaching 1,574 individuals) and no tertiary cases emerged after the campaigns. We recommend extending guidance to include actions taken that helped curb this outbreak: 1) vaccinating in secondary school and 2) broadening the household contact definition. Based on our learning we further suggest 3) vaccinating upon identification of a single case who attended school while infectious regardless of source and 4) active case finding by serologically testing contacts.


Subject(s)
Community-Acquired Infections/prevention & control , Disease Outbreaks/prevention & control , Hepatitis A Vaccines/administration & dosage , Hepatitis A/prevention & control , Hepatitis A/transmission , Mass Vaccination , Adolescent , Child , Child, Preschool , Community-Acquired Infections/epidemiology , Community-Acquired Infections/virology , Endemic Diseases , Family Characteristics , Female , Hepatitis A/epidemiology , Hepatitis A/virology , Humans , Incidence , Infant , Male , Schools , Travel
4.
Euro Surveill ; 19(24)2014 Jun 19.
Article in English | MEDLINE | ID: mdl-24970371

ABSTRACT

Six outbreaks of infectious syphilis in the United Kingdom, ongoing since 2012, have been investigated among men who have sex with men (MSM) and heterosexual men and women aged under 25 years. Interventions included case finding and raising awareness among healthcare professionals and the public. Targeting at-risk populations was complicated as many sexual encounters involved anonymous partners. Outbreaks among MSM were influenced by the use of geospatial real-time networking applications that allow users to locate other MSM within close proximity.


Subject(s)
Disease Outbreaks , Sexual Behavior , Sexual Partners , Syphilis/epidemiology , Adolescent , Contact Tracing , Female , Heterosexuality/psychology , Heterosexuality/statistics & numerical data , Homosexuality, Male/psychology , Homosexuality, Male/statistics & numerical data , Humans , Male , Population Surveillance , Risk Factors , Risk-Taking , United Kingdom/epidemiology , Young Adult
5.
Eur J Cancer ; 43(9): 1415-21, 2007 Jun.
Article in English | MEDLINE | ID: mdl-17509875

ABSTRACT

PURPOSE: The aim of this study is to describe the natural history of Hodgkin's Lymphoma (HL) in a large unselected group of children aged 5 years or below at diagnosis, who were treated on a standard treatment programme in the United Kingdom between 1982 and 2000. METHODS: Eighty-one unselected children with HL aged 5 years or under at diagnosis, treated on the United Kingdom Children's Cancer Study Group (UKCCSG) Hodgkin's trials HD1 (1982-1992) and HD2 (1992-2000), were included in the study. RESULTS: Sixty-one patients (81%) presented with early stage disease (n=66). Fifty-three patients (65%) received combination chemotherapy, 28 (34%) received involved field radiotherapy (IF-RT) and 4 patients were treated with combined modality therapy. Eighteen children relapsed after primary therapy. CONCLUSIONS: Children treated with IF-RT had a higher rate of primary treatment failures as well as increased late treatment-related morbidity.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/adverse effects , Hodgkin Disease/mortality , Adolescent , Adult , Child , Child, Preschool , Clinical Trials as Topic , Combined Modality Therapy/mortality , Disease-Free Survival , Female , Hodgkin Disease/drug therapy , Hodgkin Disease/radiotherapy , Humans , Male , Neoplasm Recurrence, Local , Radiotherapy/adverse effects , Treatment Failure , United Kingdom
6.
Clin Infect Dis ; 40(9): 1244-9, 2005 May 01.
Article in English | MEDLINE | ID: mdl-15825025

ABSTRACT

BACKGROUND: Adenovirus infections are associated with significant rates of morbidity and mortality among children after bone marrow transplantation (BMT). Many transplantation units use molecular virological methods, such as polymerase chain reaction (PCR), for surveillance for adenovirus infection and give preemptive antiviral therapy to children with evidence of disseminated adenovirus infection. This treatment strategy has never been evaluated in clinical trials. METHODS: We retrospectively tested blood samples obtained from a cohort of children who had undergone BMT before the introduction of regular weekly surveillance for adenovirus infection. A total of 273 samples collected from 26 patients between May 1998 and June 2002 were tested for adenovirus infection by quantitative PCR. Virus load was quantified for each sample yielding positive test results, and the clinical notes and virological records of each child were reviewed. RESULTS: Evidence of adenovirus infection was found in 11 children (42%), 7 of whom had not previously had positive test results. Receipt of T cell-depleted transplants was associated with a significantly higher incidence of adenovirus infection during the posttransplantation period. The 2 children who died from adenovirus disease developed infection within 2 weeks after transplantation, and both had very low absolute lymphocyte counts at the time of diagnosis. Seven of 11 children with blood samples that were found to be positive for adenovirus by PCR cleared the virus without antiviral therapy. CONCLUSIONS: Surveillance for adenovirus by PCR is better than symptomatic testing for detecting adenovirus infection. Antiviral therapy may not be necessary for all children who develop adenovirus viremia after BMT.


Subject(s)
Adenoviridae Infections/drug therapy , Adenoviridae Infections/etiology , Bone Marrow Transplantation/adverse effects , Adenoviridae/isolation & purification , Adenoviridae Infections/blood , Adolescent , Antiviral Agents/therapeutic use , Child , Child, Preschool , Feces/virology , Humans , Retrospective Studies
7.
Lancet Infect Dis ; 3(2): 79-86, 2003 Feb.
Article in English | MEDLINE | ID: mdl-12560192

ABSTRACT

Adenovirus is increasingly being recognised as a significant pathogen in children following bone marrow transplantation. The virus is endemic in the general paediatric population, and frequently causes severe disease in immunocompromised patients, especially children. Immune responses to adenovirus infection are not fully understood but T-cell responses appear to be important for recovery. Infections can affect a variety of organs with gastrointestinal and urinary tract diseases being the most common. When disseminated infection occurs, reported mortality rates are as high as 60%. The responses to treatment in immunocompromised patients have generally been disappointing. New molecular diagnostic techniques have meant that adenoviral infections can now be detected early, often before symptoms have developed. Clinicians now screen for adenovirus infection to allow early initiation of treatment. It is hoped that this approach, together with effective antiviral therapy, will reduce the deaths from this common virus in high-risk children.


Subject(s)
Adenoviridae Infections , Adenoviridae/pathogenicity , Bone Marrow Transplantation/immunology , Opportunistic Infections , Adenoviridae/classification , Adenoviridae/genetics , Adenoviridae Infections/diagnosis , Adenoviridae Infections/epidemiology , Adenoviridae Infections/immunology , Adenoviridae Infections/therapy , Bone Marrow Transplantation/adverse effects , Child , Humans , Immunity, Cellular , Immunocompromised Host , Opportunistic Infections/diagnosis , Opportunistic Infections/epidemiology , Opportunistic Infections/immunology , Opportunistic Infections/therapy , Serotyping , T-Lymphocytes/immunology
8.
Med Pediatr Oncol ; 40(3): 141-7, 2003 Mar.
Article in English | MEDLINE | ID: mdl-12518341

ABSTRACT

BACKGROUND: Survival after relapse in patients with Ewing sarcoma is very poor and this retrospective study attempts to identify of prognostic factors predicting survival after relapse. PROCEDURE: A total of 191 patients with localised Ewing sarcoma were registered in the ET-2 trial of the United Kingdom Children's Cancer Study Group (UKCCSG). All patients received standardised primary treatment with chemotherapy and surgery and or radiotherapy as local modality treatment. Sixty-four patients who relapsed are included in this report. Treatment at relapse was variable and included chemotherapy, surgery, radiotherapy and high dose therapy (HDT) or megatherapy with peripheral stem cell transplantation (PBSCT) or autologous bone marrow transplantation (ABMT) in various combinations. A subgroup of patients had only non-specific symptomatic treatment at relapse. Both univariate and multivariate methods were used to investigate variables affecting survival after relapse. RESULTS: The overall actuarial median survival from relapse for all patients was 14 months (95% CI 11-16 months). Univariate analysis showed that males had a longer survival (median, 16 months vs. 11 months); patients who relapsed while on treatment did worse (median, 3 months vs. 16 months) and patients who had a longer disease-free interval (DFI) prior to relapse had a better outcome (DFI <1 year, median survival = 3 months; DFI 1-2 years, survival = 8 months; DFI > 2 years, median survival = 24 months, P < 0.001). Multivariate analysis confirmed that duration of first remission was the only factor associated with longer survival after relapse. CONCLUSIONS: These data suggest that although aggressive therapy may delay disease progression after relapse for some children, the course of the disease after relapse is usually fatal. International co-operative studies are needed to evaluate new strategies.


Subject(s)
Bone Neoplasms/mortality , Bone Neoplasms/therapy , Neoplasm Recurrence, Local/mortality , Neoplasm Recurrence, Local/therapy , Sarcoma, Ewing/mortality , Sarcoma, Ewing/therapy , Adolescent , Adult , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Bone Neoplasms/pathology , Child , Child, Preschool , Cohort Studies , Combined Modality Therapy , Female , Humans , Male , Prognosis , Radiotherapy Dosage , Retrospective Studies , Sarcoma, Ewing/secondary , Stem Cell Transplantation , Survival Analysis , Treatment Outcome
9.
Br J Haematol ; 110(3): 547-51, 2000 Sep.
Article in English | MEDLINE | ID: mdl-10997963

ABSTRACT

A diagnosis of granulocytic sarcoma was made in a 2-year-old child based on the detection of myelomonocytic blasts in tissue obtained from a subcutaneous nodule with no evidence of concomitant disease in the bone marrow. The child responded to systemic chemotherapy and is in remission 3 years later. An identical clone with an in frame fusion of the MLL and AF10 genes was identified from both tissue and bone marrow samples. The generation of an in frame MLL-AF10 fusion requires complex intra- and interchromosomal exchanges between chromosomes 10 and 11. In this case, an intrachromosomal rearrangement of chromosome 5 was also observed. This case illustrates the presence of systemic disease in extramedullary leukaemia, its response to systemic rather than topical therapy and suggests that the events leading to chromosomal translocations in leukaemia may be part of a generalized intracellular event.


Subject(s)
Bone Marrow Cells , Chromosomes, Human, Pair 5 , Gene Rearrangement , Leukemia, Myeloid/genetics , Proto-Oncogenes , Acute Disease , Artificial Gene Fusion , DNA-Binding Proteins/genetics , Electrophoresis, Agar Gel , Female , Histone-Lysine N-Methyltransferase , Humans , In Situ Hybridization, Fluorescence , Infant , Karyotyping , Myeloid-Lymphoid Leukemia Protein , Reverse Transcriptase Polymerase Chain Reaction , Transcription Factors/genetics
10.
Eur J Cancer ; 35(12): 1698-704, 1999 Nov.
Article in English | MEDLINE | ID: mdl-10674016

ABSTRACT

Relapse patterns have been documented in 191 children with localised Ewing's sarcoma treated with the United Kingdom Children's Cancer Group (UKCCSG) Ewing's Tumour regimen ET2. All received chemotherapy comprising ifosfamide, vincristine, doxorubicin and actinomycin D. Local treatment modality was excision and or radiotherapy depending on tumour site and response to primary chemotherapy. Although not strictly comparable, due to the clinical indications used for each modality, local relapse rates were very low and were similar, irrespective of the type of local treatment modality: radiotherapy (3/56), surgery (7/114) or a combination (0/20). Combined relapse (local + distant) rates were similarly low irrespective of the type of local therapy: radiotherapy (4/56), surgery (4/114) or a combination (0/20). Overall survival was lower in females (P = < 0.04), older children (P = < 0.002) and those with primaries at sites other than long bones (P = < 0.02). It is concluded that with effective intensive chemotherapy combined with either radiotherapy or surgery, local control in this study was excellent at sites other than the pelvis. Preventing distant relapse, predominantly to lung and bone, remains the major challenge.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Bone Neoplasms/therapy , Sarcoma, Ewing/therapy , Adolescent , Adult , Aged , Aged, 80 and over , Child , Child, Preschool , Combined Modality Therapy , Dactinomycin/administration & dosage , Disease-Free Survival , Doxorubicin/administration & dosage , Female , Follow-Up Studies , Humans , Ifosfamide/administration & dosage , Infant , Male , Middle Aged , Neoplasm Metastasis , Neoplasm Recurrence, Local , Treatment Outcome , Vincristine/administration & dosage
11.
Br J Radiol ; 71(843): 336-9, 1998 Mar.
Article in English | MEDLINE | ID: mdl-9616248

ABSTRACT

There are several reports of osteosarcoma metastases to the heart. A rare case of a metastatic osteosarcoma to the endocardium of the left atrium in a 17 year old patient is described. The radiological features are discussed in detail.


Subject(s)
Bone Neoplasms/diagnostic imaging , Femoral Neoplasms/pathology , Heart Neoplasms/secondary , Lung Neoplasms/secondary , Osteosarcoma/diagnostic imaging , Osteosarcoma/secondary , Adolescent , Fatal Outcome , Female , Femoral Neoplasms/diagnostic imaging , Heart Atria , Humans , Radiography , Radionuclide Imaging
12.
Eur J Cancer ; 34(13): 2058-63, 1998 Dec.
Article in English | MEDLINE | ID: mdl-10070311

ABSTRACT

The VEEP regimen (vincristine, etoposide, epirubicin, prednisolone), with or without involved field radiotherapy, has been shown to be an effective treatment in adult Hodgkin's disease. In an attempt to avoid the late sequelae of both alkylating agents and radiotherapy this regimen has been studied in a series of 54 children and young adults. Early analysis suggested that the relapse rate was higher with VEEP than with standard alkylating agent-based regimens. Sufficient follow-up has now been achieved to evaluate the likelihood of sustained remission following second-line treatment and therefore the overall long term survival with this treatment approach. The 5-year Overall Survival (OS) and 5-year Progression Free Survival (PFS) for patients with stage I-III disease was 93% and 82% respectively. However, the 5-year OS and PFS for stage IV patients was only 44% and 50%, respectively. Of 13 patients who were initial treatment failures on VEEP, 7 of whom had advanced disease, only 6 were salvaged with second-line therapy. 8 of 33 who attained a complete response (CR) relapsed and there were 2 relapses in those achieving a partial response (PR) (n = 8). All those relapsing from CR/PR were salvaged by second-line alkylating agent chemotherapy +/- radiotherapy, +/- high dose chemotherapy. In conclusion, patients with stage I-IIIA, non-bulky disease, the moderately high relapse rate did not adversely affect the overall high cure rate, although VEEP failures were subjected to a high total treatment burden. VEEP alone is inadequate in patients with stage IV disease, bulky mediastinal disease in/or those with B symptoms in whom there is a high primary failure rate and relatively poor results with second line therapy.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Hodgkin Disease/drug therapy , Adolescent , Adult , Child , Child, Preschool , Cohort Studies , Disease Progression , Disease-Free Survival , Epirubicin/administration & dosage , Etoposide/administration & dosage , Female , Follow-Up Studies , Humans , Male , Prednisolone/administration & dosage , Recurrence , Salvage Therapy , Vincristine/administration & dosage
13.
Bone Marrow Transplant ; 20(10): 843-6, 1997 Nov.
Article in English | MEDLINE | ID: mdl-9404924

ABSTRACT

Eighteen patients with poor risk Ewing's sarcoma (including 11 patients with metastatic disease at presentation) received consolidation therapy of busulphan and melphalan with autologous stem cell rescue. There were nine females. The median age at diagnosis was 14.2 years (range 2.75-30 years). There was one early death due to cytomegalovirus pneumonitis. One patient developed a single generalised convulsion during busulphan therapy. Severe renal toxicity was not encountered. One patient developed veno-occlusive disease of the liver (VOD) which eventually resolved. With a median follow up of 2 years, 13 patients survive including six with initial metastatic disease. We conclude that high-dose busulphan/melphalan is well-tolerated and should be evaluated for efficacy in a larger series of patients with high risk Ewing's sarcoma.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Bone Neoplasms/therapy , Hematopoietic Stem Cell Transplantation , Sarcoma, Ewing/therapy , Adolescent , Adult , Anticonvulsants/therapeutic use , Bone Neoplasms/drug therapy , Bone Neoplasms/pathology , Busulfan/administration & dosage , Busulfan/adverse effects , Child , Child, Preschool , Clonazepam/therapeutic use , Combined Modality Therapy , Contraindications , Disease-Free Survival , Female , Hepatic Veno-Occlusive Disease/etiology , Humans , Male , Melphalan/administration & dosage , Neoplasm Metastasis , Phenytoin , Remission Induction , Sarcoma, Ewing/drug therapy , Sarcoma, Ewing/pathology , Seizures/chemically induced , Seizures/prevention & control , Survival Analysis , Transplantation Conditioning/adverse effects , Treatment Outcome
14.
J Clin Oncol ; 15(7): 2622-30, 1997 Jul.
Article in English | MEDLINE | ID: mdl-9215833

ABSTRACT

PURPOSE: Histology has been identified as an important prognostic factor in Hodgkin's disease (HD) in adults. Information regarding the impact of histology on outcome in childhood HD is scarce. This study determines the effect of histology on the overall survival (OS) or progression-free survival (PFS) in a national series of children treated in a standardized manner. PATIENTS AND METHODS: The results of treatment of 331 assessable patients, treated between January 1, 1982 and June 30, 1992, in the United Kingdom Children's Cancer Study Group (UKCCSG) Hodgkin's study I were reviewed to evaluate OS, PFS, and deaths according to stage and histology. Treatment was either involved-field radiation alone (stage IA) or chlorambucil, vinblastine, procarbazine, and prednisolone (ChlVPP) chemotherapy with or without mediastinal radiation. All were clinically staged at diagnosis. RESULTS: Nodular sclerosing (NS) HD was the most common histologic subtype (155 of 331 patients [47%]) and was uniformly distributed through all stages. Lymphocyte-depletion (LD) HD was extremely uncommon (< 1%). Mixed-cellularity (MC) HD had the highest relapse rate, but this was only significant (P < .05) in stage I patients who received local irradiation alone. There was no other statistically significant difference in OS and PFS between the various histologic subtypes. Multivariate analysis for PFS and OS confirmed that stage was the most important prognostic factor and that histology did not have an effect after stratification by stage. CONCLUSION: This study demonstrates that with effective multiagent chemotherapy, histologic subtype does not influence outcome. The high relapse rates in stage I MC subtype indicates that MC HD is biologically aggressive and systemic treatment with or without local irradiation may be indicated. The high relapse rate in stage IV patients appeared to be independent of histology.


Subject(s)
Hodgkin Disease/mortality , Hodgkin Disease/pathology , Actuarial Analysis , Adolescent , Child , Child, Preschool , Disease-Free Survival , Hodgkin Disease/therapy , Humans , Neoplasm Staging , Prognosis , Retrospective Studies , Survival Analysis , Treatment Outcome , United Kingdom
SELECTION OF CITATIONS
SEARCH DETAIL
...